StockData
Vistagen Therapeutics, Inc. logo

Vistagen Therapeutics, Inc. (VTGN) stock

VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.19+0.00 (+2.01%)

Close on Nov 17, 2026Market cap $8.34MP/E –Yield –

Vistagen Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Vistagen Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$69.66M. For fiscal 2026 it was -$72.13M. The highest annual figure on record is -$5.03M in fiscal 2014.

Annual operating income

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$72.13M–
FY2025Mar 31, 2025-$55.97M–
FY2024Mar 31, 2024-$33.02M–
FY2023Mar 31, 2023-$59.27M–
FY2022Mar 31, 2022-$47.78M–
FY2021Mar 31, 2021-$17.93M–
FY2020Mar 31, 2020-$20.80M–
FY2019Mar 31, 2019-$24.56M–
FY2018Mar 31, 2018-$14.20M–
FY2017Mar 31, 2017-$10.25M–
FY2016Mar 31, 2016-$17.85M–
FY2015Mar 31, 2015-$6.78M–
FY2014Mar 31, 2014-$5.03M–
FY2013Mar 31, 2013-$6.79M–
FY2012Mar 31, 2012-$9.04M–
FY2011Mar 31, 2011-$6.56M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026-$13.35M–
Q4 FY2026CQ1 2026Mar 31, 2026-$16.72M–
Q3 FY2026CQ4 2025Dec 31, 2025-$19.55M–
Q2 FY2026CQ3 2025Sep 30, 2025-$20.05M–
Q1 FY2026CQ2 2025Jun 30, 2025-$15.80M–
Q4 FY2025CQ1 2025Mar 31, 2025-$14.50M–
Q3 FY2025CQ4 2024Dec 31, 2024-$15.12M–
Q2 FY2025CQ3 2024Sep 30, 2024-$14.23M–
Q1 FY2025CQ2 2024Jun 30, 2024-$12.13M–
Q4 FY2024CQ1 2024Mar 31, 2024-$11.36M–
Q3 FY2024CQ4 2023Dec 31, 2023-$7.88M–
Q2 FY2024CQ3 2023Sep 30, 2023-$6.78M–
Q1 FY2024CQ2 2023Jun 30, 2023-$7.00M–
Q4 FY2023CQ1 2023Mar 31, 2023-$12.24M–
Q3 FY2023CQ4 2022Dec 31, 2022-$9.77M–
Q2 FY2023CQ3 2022Sep 30, 2022-$17.49M–
Q1 FY2023CQ2 2022Jun 30, 2022-$19.77M–
Q4 FY2022CQ1 2022Mar 31, 2022-$16.69M–
Q3 FY2022CQ4 2021Dec 31, 2021-$10.54M–
Q2 FY2022CQ3 2021Sep 30, 2021-$12.80M–
Q1 FY2022CQ2 2021Jun 30, 2021-$7.75M–
Q4 FY2021CQ1 2021Mar 31, 2021-$6.22M–
Q3 FY2021CQ4 2020Dec 31, 2020-$5.30M–
Q2 FY2021CQ3 2020Sep 30, 2020-$3.29M–
Q1 FY2021CQ2 2020Jun 30, 2020-$3.12M–
Q4 FY2020CQ1 2020Mar 31, 2020-$3.26M–
Q3 FY2020CQ4 2019Dec 31, 2019-$5.96M–
Q2 FY2020CQ3 2019Sep 30, 2019-$5.35M–
Q1 FY2020CQ2 2019Jun 30, 2019-$6.22M–
Q4 FY2019CQ1 2019Mar 31, 2019-$5.72M–
Q3 FY2019CQ4 2018Dec 31, 2018-$7.19M–
Q2 FY2019CQ3 2018Sep 30, 2018-$7.43M–
Q1 FY2019CQ2 2018Jun 30, 2018-$4.21M–
Q4 FY2018CQ1 2018Mar 31, 2018-$4.08M–
Q3 FY2018CQ4 2017Dec 31, 2017-$2.87M–
Q2 FY2018CQ3 2017Sep 30, 2017-$4.99M–
Q1 FY2018CQ2 2017Jun 30, 2017-$2.26M–
Q4 FY2017CQ1 2017Mar 31, 2017-$2.55M–
Q3 FY2017CQ4 2016Dec 31, 2016-$2.64M–
Q2 FY2017CQ3 2016Sep 30, 2016-$3.10M–

More Vistagen Therapeutics figures

See a number that looks wrong?